Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited and was publicly listed in
Panacea Biotec Q4FY23 Earnings Story
Categories
Biotechnology
Panacea Biotec Q4FY23; 8% Fall in Revenues
Panacea Biotec Ltd.’s revenue in Q4FY23 rose 13% to ₹ 12,557 crores. Consolidated Profit After Tax came at ₹ 4,320 crores in
Laurus Labs Limited Q4 FY23 Earnings Conference Call Insights
https://youtu.be/5Vtl-XMN8qg Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY23 Earnings Concall Management Update: [00:09:24]LAURUSLABS said it invested in expanding non-ARV formulation
Laurus Labs Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY23 Earnings Concall Management Update: [00:03:57] LAURUSLABS said its strong results were driven by
Syngene International Ltd (SYNGENE) Q3 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Syngene reported a 5% rise in its net profit for Q3FY23
Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted
Syngene International Ltd (SYNGENE) Q3 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated January 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Shares of Biocon research arm soars as it reports 23% rise in its revenue
Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted
Biocon Limited (BIOCON) Q2 FY23 Earnings Concall Transcript
Biocon Limited (NSE: BIOCON) Q2 FY23 Earnings Concall dated Nov. 14, 2022 Corporate Participants: Saurabh Paliwal -- Head, Investor Relations Kiran Mazumdar
Dishman Carbogen Amcis Ltd (DCAL) Q2 FY22 Earnings Concall Transcript
Dishman Carbogen Amcis Ltd (NSE: DCAL) Q2 FY22 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Arpit Vyas -- Global Managing Director Pascal Villemagne -- Vice
Laurus Labs Limited Q2 FY23 Earnings Conference Call Insights
https://youtu.be/ZaM0EH45MvA Key highlights from Laurus Labs Limited (LAURUSLABS) Q2 FY23 Earnings Concall Management Update: [00:10:45] LAURUSLABS said that on the R&D front,
Laurus Labs Limited (LAURUSLABS) Q2 FY23 Earnings Concall Transcript
Laurus Labs Limited (NSE:LAURUSLABS) Q2 FY23 Earnings Concall dated Oct. 21, 2022 Corporate Participants: Satyanarayana Chava -- Chief Executive Officer V.V. Ravi Kumar -- Chief Financial Officer Analysts:
Laurus Labs Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/gMXrmnAGz9Y Key highlights from Laurus Labs Limited (LAURUSLABS) Q1 FY23 Earnings Concall Management Update: LAURUSLABS said it expects the US filing pace
Laurus Labs Limited Q4 FY22 Earnings Conference Call Insights
https://youtu.be/83rl6ffkU9c Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY22 Earnings Concall Management Update: LAURUSLABS said that based on its healthy product
Laurus Labs Limited Q3 FY22 Earnings Conference Call Insights
https://www.youtube.com/watch?v=Q_K9qU7RXvI Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY22 Earnings Concall Management Update: In 3Q, the company faced some interim challenges
Infographic: All you need to know about Dr Reddy’s Labs Q2 performance
Dr. Reddy's Laboratories(NSE:DRREDDY) recently reported its second-quarter 2022 earnings results. The company had a consolidated revenue of ₹5,992 crores with a growth